Browsing by Author "Barriga Cosmelli, María Isabel"
Now showing 1 - 6 of 6
Results Per Page
Sort Options
- ItemDetección precoz del cáncer cervicouterino en Chile : tiempo para el cambio(2014) Leniz Martelli, Javiera; Van De Wyngard, V.; Lagos Lucero, Sonia Marcela; Barriga Cosmelli, María Isabel; Puschel Illanes, Klaus; Ferreccio Readi, Catterina
- ItemExamen de detección de virus papiloma humano en el tamizaje de cáncer cervicouterino en un Servicio de Salud de Santiago, Chile(2015) Terrazas, Solana; Ibáñez Cáceres, Carolina; Lagos, Marcela; Poggi, Helena; Brañes, Jorge; Barriga Cosmelli, María Isabel; Cartagena, Jaime; Núñez, Felipe; González, Francisca; Cook, María Paz; Van De Wyngard, Vanesa; Ferreccio Readi, Catterina; Terrazas, Solana; Ibáñez Cáceres, Carolina; Lagos, Marcela; Poggi, Helena; Brañes, Jorge; Barriga, María I.; Cartagena, Jaime; Núñez, Felipe; González, Francisca; Cook, María Paz; Van De Wyngard, Vanesa; Ferreccio Readi, Catterina
- ItemHPV vaginal self-sampling among women non-adherent to Papanicolaou screening in Chile(2013) Léniz Martelli, Javiera; Barriga Cosmelli, María Isabel; Lagos Lucero, Marcela; Ibáñez Cáceres, Carolina; Puschel Illanes, Klaus; Catterina Ferreccio
- ItemHPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile(2015) Lagos Lucero, Marcela; Van De Wyngard, Vanessa; Poggi, Helena; Cook, María Paz; Viviani García, Paola; Barriga Cosmelli, María Isabel; Ferreccio Readi, Catterina; Pruyas, Martha; Lagos Lucero, Marcela; Van De Wyngard, Vanessa; Poggi, Helena; Cook, María Paz; Viviani, Paola; Barriga, María I.; Ferreccio Readi, Catterina; Pruyas, MarthaAbstract Background We previously conducted a population-based screening trial of high-risk human papillomavirus (hrHPV) testing and conventional cytology, demonstrating higher sensitivity (92.7 % vs 22.1 % for CIN2+) but lower positive predictive value (10.5 % vs 23.9 %) of hrHPV testing. Here we report the performance of HPV16/18 genotyping to triage the hrHPV positive participants. Methods Women aged 25 years and older received hrHPV (Hybrid Capture 2) and Papanicolaou testing; positives by either test underwent colposcopy and directed biopsy, as did a sample of double-negatives. hrHPV positive women were reflex-tested with HPV16/18 genotyping (Digene HPV Genotyping PS Test). Results Among the 8,265 participants, 10.7 % were hrHPV positive, 1.7 % had ASCUS+ cytology, 1.2 % had CIN2+; 776 (88 %) hrHPV positive women had complete results, of whom 38.8 % were positive for HPV16 (24.0 %), HPV18 (9.7 %) or both (5.1 %). CIN2+ prevalence in HPV16/18 positive women (16.3 %, 95 % CI 12.3-20.9) was twice that of HPV16/18 negative women (8.0 %, 95 % CI 5.7-10.8). HPV16/18 genotyping identified 40.5 % of CIN2, 66.7 % of CIN3 and 75.0 % of cancers. Compared to hrHPV screening alone, HPV16/18 triage significantly reduced the referral rate (10.7 % vs 3.7 %) and the number of colposcopies required to detect one CIN2+ (9 vs 6). When HPV16/18 negative women with baseline ASCUS+ cytology were also colposcopied, an additional 14 % of CIN2+ was identified; referral increased slightly to 4.2 %. Conclusions HPV16/18 triage effectively stratified hrHPV positive women by their risk of high-grade lesions. HPV16/18 positive women must be referred immediately; referral could be deferred in HPV16/18 negative women given the slower progression of non-HPV16/18 lesions, however, they will require active follow-up.Abstract Background We previously conducted a population-based screening trial of high-risk human papillomavirus (hrHPV) testing and conventional cytology, demonstrating higher sensitivity (92.7 % vs 22.1 % for CIN2+) but lower positive predictive value (10.5 % vs 23.9 %) of hrHPV testing. Here we report the performance of HPV16/18 genotyping to triage the hrHPV positive participants. Methods Women aged 25 years and older received hrHPV (Hybrid Capture 2) and Papanicolaou testing; positives by either test underwent colposcopy and directed biopsy, as did a sample of double-negatives. hrHPV positive women were reflex-tested with HPV16/18 genotyping (Digene HPV Genotyping PS Test). Results Among the 8,265 participants, 10.7 % were hrHPV positive, 1.7 % had ASCUS+ cytology, 1.2 % had CIN2+; 776 (88 %) hrHPV positive women had complete results, of whom 38.8 % were positive for HPV16 (24.0 %), HPV18 (9.7 %) or both (5.1 %). CIN2+ prevalence in HPV16/18 positive women (16.3 %, 95 % CI 12.3-20.9) was twice that of HPV16/18 negative women (8.0 %, 95 % CI 5.7-10.8). HPV16/18 genotyping identified 40.5 % of CIN2, 66.7 % of CIN3 and 75.0 % of cancers. Compared to hrHPV screening alone, HPV16/18 triage significantly reduced the referral rate (10.7 % vs 3.7 %) and the number of colposcopies required to detect one CIN2+ (9 vs 6). When HPV16/18 negative women with baseline ASCUS+ cytology were also colposcopied, an additional 14 % of CIN2+ was identified; referral increased slightly to 4.2 %. Conclusions HPV16/18 triage effectively stratified hrHPV positive women by their risk of high-grade lesions. HPV16/18 positive women must be referred immediately; referral could be deferred in HPV16/18 negative women given the slower progression of non-HPV16/18 lesions, however, they will require active follow-up.
- ItemPlatelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells.(2015) Orellana, Renan.; Kato Cardemil, Sumie Rode; Erices, Rafaela.; Bravo Castillo, María Loreto; González Hevia, Pamela Andrea.; Oliva, Bárbara.; Cubillos Alfaro, Sofía María Jesús.; Valdivia Román, Andrés Felipe; Brañes, Jorge; Cuello F., Mauricio; Ibañez, Carolina; Barriga Cosmelli, María Isabel; Bravo, Erasmo.; Alonso, Catalina.; Bustamente, Eva.; Castellon, Enrique.; Hidalgo, Patricia.; Trigo, Cesar.; Panes Becerra, Olga Teresa; Pereira Garcés, Jaime Ignacio; Mezzano, Diego; Owen, Gareth IvorAbstract Background An increase in circulating platelets, or thrombocytosis, is recognized as an independent risk factor of bad prognosis and metastasis in patients with ovarian cancer; however the complex role of platelets in tumor progression has not been fully elucidated. Platelet activation has been associated with an epithelial to mesenchymal transition (EMT), while Tissue Factor (TF) protein expression by cancer cells has been shown to correlate with hypercoagulable state and metastasis. The aim of this work was to determine the effect of platelet-cancer cell interaction on TF and “Metastasis Initiating Cell (MIC)” marker levels and migration in ovarian cancer cell lines and cancer cells isolated from the ascetic fluid of ovarian cancer patients. Methods With informed patient consent, ascitic fluid isolated ovarian cancer cells, cell lines and ovarian cancer spheres were co-cultivated with human platelets. TF, EMT and stem cell marker levels were determined by Western blotting, flow cytometry and RT-PCR. Cancer cell migration was determined by Boyden chambers and the scratch assay. Results The co-culture of patient-derived ovarian cancer cells with platelets causes: 1) a phenotypic change in cancer cells, 2) chemoattraction and cancer cell migration, 3) induced MIC markers (EMT/stemness), 3) increased sphere formation and 4) increased TF protein levels and activity. Conclusions We present the first evidence that platelets act as chemoattractants to cancer cells. Furthermore, platelets promote the formation of ovarian cancer spheres that express MIC markers and the metastatic protein TF. Our results suggest that platelet-cancer cell interaction plays a role in the formation of metastatic foci.
- ItemScreening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile(2013) Ferreccio Readi, Catterina; Barriga Cosmelli, María Isabel; Lagos Lucero, Marcela; Ibáñez Cáceres, Carolina; Poggi, Helena; González, F.; Terrazas Martins, Solana; Katki, H.; Núñez, F.; Cartagena, J.; Van De Wyngard, V.; Vinales, D.; Brañes, Jorge